Shin Do Young, Yi Dae Yong, Jo Soojin, Lee Yoo Min, Kim Jong-Hwa, Kim Wonyong, Park Mi Ri, Yoon Seok Min, Kim Yunsik, Yang Siyoung, Lim In Seok
Department of Pediatrics, Chung-Ang University Hospital.
College of Medicine, Chung-Ang University, Seoul.
Medicine (Baltimore). 2020 Sep 18;99(38):e22192. doi: 10.1097/MD.0000000000022192.
Rotavirus is one of the most common causes of infantile enteritis. In common enterocolitis, probiotic organisms, including Lactobacilli, are effective in treating diarrhea. A new species, Lactobacillus plantarum (LRCC5310), which was shown to inhibit the adherence and proliferation of rotavirus in the small intestine through animal experiments, was investigated for the efficacy and safety of patients with rotaviral enteritis.
LRCC5310 (Group I) and control (Group II) groups consisting of children who were hospitalized for rotaviral enteritis were compared, and the medical records of patients (Group III) who were hospitalized for rotaviral enteritis during the same study period were retrospectively analyzed. Clinical symptoms were compared and stool samples were collected to compare changes in virus multiplication between Groups I and II.
Groups I, II, and III comprised 15, 8, and 27 children, respectively. There were no differences in clinical information among the groups at admission. In Group I, a statistically significant improvement was noted in the number of patients with diarrhea, number of defecation events on Day 3, and total diarrhea period as opposed to Group II (P = .033, P = .003, and P = .012, respectively). The improvement of Vesikari score in Group I was greater than that in the other groups (P = .076, P = .061, and P = .036, respectively). Among rotavirus genotypes, 9 (22.5%) strains and 8 (20.0%) strains belonged to the G9P8 and G1P8 genotypes, respectively. The virus reduction effect, as confirmed via stool specimens, was also greater in Group I. No significant side effects were noted in infants.
LRCC5310 improved clinical symptoms, including diarrhea and Vesikari score, and inhibited viral proliferation in rotaviral gastroenteritis.
轮状病毒是婴儿肠炎最常见的病因之一。在常见的小肠结肠炎中，包括乳酸杆菌在内的益生菌对治疗腹泻有效。一种新的物种，植物乳杆菌（LRCC5310），经动物实验表明可抑制轮状病毒在小肠中的黏附和增殖，本研究对其治疗轮状病毒性肠炎患者的疗效和安全性进行了调查。
比较因轮状病毒性肠炎住院的儿童组成的LRCC5310组（第一组）和对照组（第二组），并回顾性分析同一研究期间因轮状病毒性肠炎住院的患者（第三组）的病历。比较临床症状，并收集粪便样本以比较第一组和第二组之间病毒增殖的变化。
第一组、第二组和第三组分别包括15名、8名和27名儿童。入院时各组的临床信息无差异。与第二组相比，第一组腹泻患者数量、第3天排便次数和总腹泻期有统计学意义的改善（分别为P = 0.033、P = 0.003和P = 0.012）。第一组韦西卡里评分的改善大于其他组（分别为P = 0.076、P = 0.061和P = 0.036）。在轮状病毒基因型中，分别有9株（22.5%）和8株（20.0%）属于G9P8和G1P8基因型。经粪便标本证实，第一组的病毒减少效果也更大。婴儿未出现明显副作用。
LRCC5310改善了包括腹泻和韦西卡里评分在内的临床症状，并抑制了轮状病毒性胃肠炎中的病毒增殖。
